Special Issue "Protein Kinases and Their Inhibitors in CNS Diseases"
Deadline for manuscript submissions: 31 July 2021.
Interests: drug design; medicinal chemistry; neurodegenerative diseases; pharmacology
Special Issues and Collections in MDPI journals
Prof. Dr. Ana Martínez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- protein kinase inhibitors
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1.Title: CK1-derived peptides as novel tools inhibiting the interactions between CK1 and APP695 to modulate the pathogenic metabolism of APP
Authors: Aileen Roth, Katja Mayer, Julian Beyrle, Irina König, Fabian Gärtner, Christoph Michalski, Uwe Knippschild and Joachim Bischof
Abstract: AD is a progressive neurodegenerative disorder, which is characterized by irreversible changes of specific neurons in the brain, leading to cognitive impairment followed by a mental and functional decline. Generally, AD is responsible for more than 80% of dementia cases in elderly people worldwide. Published data demonstrated a possible role for CK1 in the pathogenesis of AD by influencing the metabolism of tau and APP, which finally leads to formation of neurofibrillary tangles (NFTs) and accumulation of Aβ plaques followed by neuronal cell death. Therefore, CK1 can be seen as a therapeutic target in AD. An innovative strategy in treating AD could consequently be based on peptide inhibitors, which specifically modulate the interaction between CK1 and APP without impairing CK1 kinase activity in general. In this study, CK1-derived peptides manipulating the interaction between CK1δ/ε and APP695 were first identified by interaction analysis. Subsequently, dose-dependent effects on CK1-mediated phosphorylation of APP695 was detected for selected CK1-derived peptides in vitro. Most of these peptides also successfully passed the cell membrane in cell entry analysis and were finally tested for their effects on cellular APP metabolism. In summary, the results obtained in this study provide new insights to the interactions of CK1 with APP695 and identified CK1-derived peptides as promising approach for the development of novel pharmacological tools for the treatment of AD.